Novo Nordisk AS' and Sanofi's respective basal insulin/GLP-1 agonist fixed-ratio combination products, Xultophy and Soliqua, gained FDA approval Nov. 21 with narrower indications and different labeling than originally proposed.
Notably, the two drugs were approved the same day despite Sanofi's redemption of a priority review voucher that had earned...






